TXNRD2 and prostate carcinoma: More relevant to our work, it has been shown that miR-17-3p downregulates important anti-oxidant enzymes, such as manganese superoxide dismutase, glutathione peroxidase-2 and thioredoxin reductase-2 (TrxR2) in prostate cancer cell lines [48] and blood mononuclear cells [76].